A NEW ERA OF EXPERIENTIAL MEDICINE: FROM VIDEO GAMES TO PSYCHEDELICS
A fundamental challenge of our health-care system is the enhancement of cognition for millions of people who suffer from psychiatric and neurological conditions. Despite 70 years of global effort in attempting to identify molecules deliverable as pills to accomplish this goal, we have largely failed to deliver truly effective, accessible and low-side-effect treatments for cognitive impairments associated with medical conditions, including depression, anxiety, PTSD, ADHD and dementia.
It is important to be aware that for thousands of years we humans have been creating experiences to enhance the quality of our lives and support our mental health. However, this approach has largely been marginalized as “alternative” and has not been embraced within the core of mainstream medicine. Dr. Adam Gazzaley will describe his mission to develop and validate experiences as medicine by integrating neuroscience-guided design, invention and experimentation. In this talk, he will discuss his invention of a closed-loop video game that has now become the first FDA-cleared video game for any medical condition, and the first digital treatment for ADHD. He will share how the next generation of experiential medicine will incorporate advances in artificial intelligence, sensory immersion, virtual reality, multimodal physiological recordings and noninvasive electrical brain stimulation. He will conclude with a deep dive into his newest undertakings to explore the intricacies and possibilities of one of man’s oldest experiential medicines—psychedelics.
Dr. Adam Gazzaley obtained an M.D. and Ph.D. in neuroscience at the Mount Sinai School of Medicine in New York, completed neurology residency at the University of Pennsylvania and postdoctoral training in cognitive neuroscience at the University of California, Berkeley. He is currently the David Dolby Distinguished Professor of Neurology, Physiology and Psychiatry at the University of California, San Francisco and the founder and executive director of Neuroscape, a translational neuroscience center at UCSF engaged in technology creation and scientific research.